06:38:32 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Duearity AB

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-03 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-05-13 Ordinarie utdelning DEAR 0.00 SEK
2024-02-22 Bokslutskommuniké 2023
2024-01-31 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning DEAR 0.00 SEK
2023-04-12 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning DEAR 0.00 SEK
2022-04-07 Årsstämma 2022

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Duearity är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling och produktion av tekniska lösningar för behandling och lindring av tinnitus. Produktportföljen inkluderar exempelvis bolagets egenutvecklade produkter Tinearity och Duearity. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs inom Sverige.
The tinnitus product Tinearity G1 has received market approval in the UK
2023-04-26 14:52:00

Today Tinearity G1 received certification for the UK, which means that the product has been approved for sale. The UK has the potential to be a significant market for Duearity as tinnitus is a problem that is widely recognized.

The market approval means that Duearity can start sales in the UK. Tinnitus is widely noticed in the UK and white noise, which is obtained using the Tinearity G1, is a method widely recommended by the profession.

Tinearity G1 is a non-invasive medical device that sends white noise to the inner ear with the aim of relieving tinnitus. The Tinearity G1 can also be used when a person is undergoing Tinnitus Retraining Therapy, which is the most recommended method of treating tinnitus.

For more information, please contact

Fredrik Westman, CEO
+46 738 - 145 215
fredrik.westman@duearity.com 
www.duearity.com

About Duearity AB (publ)

Duearity is a medtech company that develops and produces solutions aiming to relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. With a deep understanding of the people who have problems with tinnitus, the Company will with intelligent solutions give these people the opportunity to enjoy life. The company will offer the products Tinearity and Tinearity-AI. Tinearity transmits white noise using Bone Conduction Technology to the inner ear in order to relieve symptoms. Tinearity AI will use artificial intelligence to help people anticipate the symptoms and relieve their discomfort. The company's headquarters are located in Malmö, Sweden.
www.duearity.com.
www.tinearity.com

Attachments

The tinnitus product Tinearity G1 has received market approval in the UK

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden